Thought for the board that I shared on another investor board.

Incelldx recently filed a patent for their Active COVID19 Severity Scale, which is an “algorithm using machine learning, built on a tailored panel of cytokines and chemokines specific for abnormalities in cytokine storm conditions.” This scale can identify the severity a patient will progress to early in the COVID19 disease process. Below is a link to the pre-publish article on the scale.

https://www.prnewswire.com/news-releases/ince...20951.html

https://www.biorxiv.org/content/10.1101/2020.12.16.423122v1

CD10 demonstrated that leronlimab caused a statically significant reduction in M2M COVID19 patient’s NEWS2 scores. If you’re not familiar with NEWS2, it’s the National Early Warning Scale and is used to more quickly identify acute illness in patients and treat them before they progress along the severity scale. “In all treated patients, at the End of Treatment (or Day 14), patients in the leronlimab group were more than twice as likely to experience a beneficial improvement in scores (NEWS2) compared to patients in the placebo group (50% vs 20%; p=0.0223). Data from the S/C trial will further solidify that leronlimab lowers patient’s NEWS2 score.

https://www.england.nhs.uk/ourwork/clinical-p...ningscore/

https://www.cytodyn.com/newsroom/press-releas...ne-results

So, if everything goes as planned (leronlimab approved for COVID19), it’s possible that a positive COVID19 patient can be identified as being at risk for hospitilization by using Incelldx’s Active COIVD19 Severity Scale and then treated with leronlimab to prevent that progression. This would heavily reduce the burden on in-patient hospital services that COVID19 is causing, as well as reduce mortality. Supply of leronlimab is an issue but I believe if EUA/approval occurs, there will be government assistance from around the world to produce more leronlimab, especially when considering that COVID19 is going to be an issue for years to come.